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Estrogen (E) and epidermal growth factors (EGF) receptors were assayed in the liver of 
nine patients with hepatocellular carcinoma (HCCl. Total E and nuclear E receptors were 
decreased significantlY in neoplasllc tissue as compared to the levels found in surrounding 
nonneoplastic tissue, The EGF receptor was decreased also in neoplastic tissue, On the 
basis of binding data. a decrease in the number but not in affinity of both the £ and EGF 
receptors was found. 
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Epidermal growth factor (EGF) is a polypeptide 
growth factor that was isolated originally from the 
submaxillary gland. It stimulates DNA synthesis in 
vitro in a variety of different cells (1-3). This effect 
is initiated by the interaction of EGF with a specific 
plasma membrane receptor (4). During the last five 
years. several lines of evidence have demonstrated 
that EGF receptor expression can be altered by 
hormones such as estrogen (E) (4), growth hormone 
(5). and thyroid stimulating hormone (TSH) (6) in 
target tissues for these hormones. 
The relationship between E and EGF has been 
studied extensively in normal uterus and in breast 
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cancer tissue (4-7). For example. it has been shown 
that E stimulates EGF receptor expression in uter-
ine tissue obtained from immature rats (4). In con-
trast, an inverse relationship exists between the 
EGF and E receptors content in breast cancer 
tissues (8). Recently it has been shown that the liver 
is also a target tissue for sex hormones (9-11). E 
receptors (ER) appear to play an important role in 
hepatic regeneration where a strong temporal rela-
tionship between increased hepatic ON A synthesis 
and an increased activity and nuclear distribution of 
ER have been found. Because both ER and EGF 
are involved in hepatocyte proliferation. the pattern 
of E and EGF receptors in tissue samples obtained 
from patients with hepatocellular carcinoma (HCC) 
was studied. 
MATERIALS AND METHODS 
.Liver Specimens. Samples of HCC-containing and nor-
ma! adjacent liver were collected from patients undergo-
ing resection in Milan. Bari. and Pittsburgh. Both tumor 
and adjacent normal liver tissue were collected and their 
identities confirmed by histology. The samples were 
wrapped in aluminum foil. snap-frozen. and stored at 
-700 C until assayed for their content of E and EGF 
receptors, Prior studies using fresh and frozen liver have 
showed that both the E and EGF receptors are stable 
during frozen storage. 
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Fig l. Estrogen receptor actlvltv In HCC ( D) and surroundmg 
normal tissues I CJ). ER activity was measured m cytosollc 
(middle panell and nuclear Ilower panell fractions of HCC and 
normal liver tissue. Total receptor IIOP panel I content was 
calculated by adding the values for nuclear and cytosolic recep-
tor. 
Materials. Radioactive [2.3.6.7-1H)estradiol ([lH)E.). 
90 Cilmmol and [I2'I]EGF were purchased from New 
England Nuclear. The purity of the radiolabeled com-
pounds was assessed periodically by thin-layer or column 
chromatography (12). Sources of other materials were as 
described previously (12-14), 
Binding Studies. The preparation of cytosolic. nuclear. 
and plasma membrane fractions was as described previ-
ously (10. 15). The methods for the estrogen receptor 
assay (10) and the EGF binding assay have been de· 
scnbed previously (15). 
Other Methods. Protein concentrations were deter-
mmed by the method of Lowry et al (16). DNA concen-
trations of homogenates and the nuclear preparations 
were determined by the method of l(jssane and Robins 
(17). Statistical analyses were performed using the Hew-
lett-Packard 9815S. The radioactivity content of tritiated 
samples was determined using a Packard TriCarb 4530 
with an automatic dpm option. ACS scintillant (Amer-
sham. was used for single-phase counting of tritium-
containing samples. 
RESULTS 
The clinical characteristics of the patients studied 
have been reported in an earlier paper (18). Figure I 
shows the E receptor activity which was quanti-
tated in both the cytosolic and nuclear fraction as 
well as in whole tissue. The results are expressed as 
femtomoles E bound per gram wet liver. The bind-
ing capacity of the cytosolic ER was different 
between nonneoplastic and neoplastic tissue. A 
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Fig 1. EGF receptor activity in plasma membranes derived from 
HCC E~F and normal liver specimens (0). 
trend for an increase in cytosolic E receptors con-
tent in cancerous tissue was evident. The nuclear 
ER content was significantly lower in neoplastic 
than in nonneoplastic tissue from the same patient 
(P < 0.05). Additionally total ER content was 
reduced in the neoplastic tissue as compared to the 
nonneoplastic tissue (P < 0.025). 
Figure 2 shows the EGF binding of plasma mem-
branes isolated from cancerous and surrounding 
normal hepatic tissue. The values are expressed as 
femtomoles EGF bound per milligram of membrane 
protein. It can be seen that hepatic membranes 
isolated from neoplastic tissue have a lower content 
of EGF receptor than do membranes isolated from 
nonneoplastic tissue. The binding affinity data dem-
onstrate that the KD values were similar for normal 
and neoplastic tissue. demonstrating that the ob-
served reduction in binding is a result of a reduction 
in number. not affinity. of the receptor. 
DISCUSSION 
Several lines of evidence have demonstrated a 
direct relationship between E and EGF receptors. 
First. the administration of estrogen increases the 
EGF receptor content in the uterus of immature 
female rats (4). Second. a similar effect has been 
reponed also in normal breast tissue (7). Recently it 
has been demonstrated that E may playa role in the 
regulation of hepatic regeneration in that there is a 
strong temporal relationship between hepatic DNA 
synthesis and the nuclear ER content of regenerat-
ing liver. In this same model. a reduction in the 
EGF receptor binding capacity of the liver has been 
shown to correlate with the increase in EGF recep-
tors. These results have been extended recently in 
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an in vitro model where hepatocytes treated with 
estrogen have been shown to lose their capacity for 
EGF-induced stimulation of proliferation (19). 
These data suggest the existence of a relationship 
between E receptors. EGF receptors. and tissue 
growth. Several additional lines of evidence indi-
cate that EGF is involved in proliferation of both 
normal and neoplastic hepatic tissue. Recently it 
has become clear that EGF is synthesized at several 
sites in the body (20-22) and that EGF functions 
more in a paracrine rather than endocrine manner. 
Considering these facts. it is possible that the reg-
ulation of EGF expression in a particular tissue 
such as the liver might be under endocrine control 
and help to explain the relationships between TSH 
and the EGF receptor production in the thyroid. 
estrogen and the EGF receptor in the uterus. and 
growth hormone as well as estrogens and the EGF 
receptor in the liver. 
The usual relationship in normal tissue between E 
and EGF may be altered in neoplastic tissue. In 
fact. Sainsbury et al (8) recently have reported a 
significant inverse relationship exists between the 
activity of the EGF receptor and the E receptor in 
primary breast cancer·tissue. Moreover. EGF re-
ceptor was found in tissues with a greater frequency 
of metastases. presumably having a greater prolif-
erative activity but were E receptor-negative. The 
results reported here demonstrate that the usual 
relationship between E receptors and EGF recep-
tors existing in nonnal tissue is altered in neoplastic 
hepatic tissue. particularly when there is an overall 
reduction in the number of EGF receptors (Figure 
2). 
It is significant that this reduction in EGF recep-
tor content in HCC is proportional to the reduction 
in ER found in the same tissue and correlates best 
with a reduction in nuclear E receptor content. It is 
well known that the nuclear E receptor number is 
the most biologicaUy imponant fraction of the total 
E receptor content of hepatic tissue. The number 
receptor fraction controls the synthetic activity 
specific for E (23. 24). In relation to these data it is 
interesting to note that a reduction in EGF receptor 
content occurs also in regenerating rat liver but is 
coupled to an increase in the number of nuclear E 
receptors. These data demonstrate that in HCC 
tissue. a reduction in EGF receptor content that is 
not coupled with an increase in E receptor content 
occurs. The reasons for and importance of this 
unusual relationship between E and EGF receptor 
content in HCC is not known. It may be that. while 
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regenerating rat liver is characterized by rapid pro-
liferation. the growth is tightly regulated and is 
transient: no permanent growth-controlling alter-
ations in the tissue have occurred and the tissue 
becomes normal once appropriate growth has con-
cluded. In the case of HCC. the proliferative activ-
ity is not regulated by the normal regulatory signals. 
It is also possible that in neoplastic tissue (25. 26). 
the EGF receptors are saturated by other growth 
factors that bind to the receptor such as alpha-TGF. 
a newly characterized growth substance. which also 
stimulates cell proliferation via an interaction with 
the EGF receptor. 
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